These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 11863117

  • 1. A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer.
    Blanke CD, Shultz J, Cox J, Modiano M, Isaacs R, Kasimis B, Schilsky R, Fleagle J, Moore M, Kemeny N, Carlin D, Hammershaimb L, Haller D.
    Ann Oncol; 2002 Jan; 13(1):87-91. PubMed ID: 11863117
    [Abstract] [Full Text] [Related]

  • 2. Trimetrexate as biochemical modulator of 5-fluorouracil/leucovorin in advanced colorectal cancer: final results of a randomised European study.
    Punt CJ, Keizer HJ, Douma J, Skovsgaard T, Schüller J, Muller EW, Ten Napel CH, Croles JJ, Lochs H, Zhang J, Hammershaimb L.
    Ann Oncol; 2002 Jan; 13(1):81-6. PubMed ID: 11865814
    [Abstract] [Full Text] [Related]

  • 3. Integrated analysis of overall survival in two randomised studies comparing 5-fluorouracil/leucovorin with or without trimetrexate in advanced colorectal cancer.
    Punt CJ, Blanke CD, Zhang J, Hammershaimb L.
    Ann Oncol; 2002 Jan; 13(1):92-4. PubMed ID: 11865815
    [Abstract] [Full Text] [Related]

  • 4. Trial of sequential trimetrexate, fluorouracil, and high-dose leucovorin in previously treated patients with gastrointestinal carcinoma.
    Conti JA, Kemeny N, Seiter K, Goker E, Tong W, André M, Ragusa K, Bertino JR.
    J Clin Oncol; 1994 Apr; 12(4):695-700. PubMed ID: 7512128
    [Abstract] [Full Text] [Related]

  • 5. Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    Köhne CH, Wils J, Lorenz M, Schöffski P, Voigtmann R, Bokemeyer C, Lutz M, Kleeberg C, Ridwelski K, Souchon R, El-Serafi M, Weiss U, Burkhard O, Rückle H, Lichnitser M, Langenbuch T, Scheithauer W, Baron B, Couvreur ML, Schmoll HJ, European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952.
    J Clin Oncol; 2003 Oct 15; 21(20):3721-8. PubMed ID: 12963704
    [Abstract] [Full Text] [Related]

  • 6. Trimetrexate: review and current clinical experience in advanced colorectal cancer.
    Blanke CD, Messenger M, Taplin SC.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 18):S18-57-S18-63. PubMed ID: 9420022
    [Abstract] [Full Text] [Related]

  • 7. Double modulation of 5-fluorouracil by trimetrexate and leucovorin in patients with advanced colorectal carcinoma.
    Machiavelli MR, Salum G, Pérez JE, Ortiz EH, Romero AO, Bologna F, Vallejo CT, Lacava JA, Dominguez ME, Leone BA.
    Am J Clin Oncol; 2004 Apr 15; 27(2):149-54. PubMed ID: 15057154
    [Abstract] [Full Text] [Related]

  • 8. Biomodulation of 5-fluorouracil with antifolates.
    Bertino JR.
    Semin Oncol; 1997 Oct 15; 24(5 Suppl 18):S18-52-S18-56. PubMed ID: 9420021
    [Abstract] [Full Text] [Related]

  • 9. Sequential trimetrexate, 5-fluorouracil and folinic acid are effective and well tolerated in metastatic colorectal carcinoma. The phase II study group of the AIO.
    Szelényi H, Hohenberger P, Lochs H, Haboubi N, Berdel WE, Thiel E, Kreuser ED.
    Oncology; 2000 May 15; 58(4):273-9. PubMed ID: 10838491
    [Abstract] [Full Text] [Related]

  • 10. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
    Hoff PM, Hochhaus A, Pestalozzi BC, Tebbutt NC, Li J, Kim TW, Koynov KD, Kurteva G, Pintér T, Cheng Y, van Eyll B, Pike L, Fielding A, Robertson JD, Saunders MP.
    J Clin Oncol; 2012 Oct 10; 30(29):3596-603. PubMed ID: 22965965
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma: a Southern Italy Cooperative Oncology Group phase II-III randomized trial.
    Comella P, De Vita F, Mancarella S, De Lucia L, Biglietto M, Casaretti R, Farris A, Ianniello GP, Lorusso V, Avallone A, Cartenì G, Leo SS, Catalano G, De Lena M, Comella G.
    Ann Oncol; 2000 Oct 10; 11(10):1323-33. PubMed ID: 11106123
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Biomodulation of Fluorouracil in colorectal cancer.
    Ardalan B, Luis R, Jaime M, Franceschi D.
    Cancer Invest; 1998 Oct 10; 16(4):237-51. PubMed ID: 9589033
    [Abstract] [Full Text] [Related]

  • 15. A phase II study of irinotecan alternated with a weekly schedule of oxaliplatin, high-dose leucovorin and 48-hour infusion 5-fluorouracil in patients with advanced colorectal cancer.
    Rosati G, Tucci A, Rinaldi A, Colarusso D, Pizza C, Reggiardo G, Manzione L.
    Oncology; 2004 Oct 10; 66(5):371-8. PubMed ID: 15331924
    [Abstract] [Full Text] [Related]

  • 16. The impact of adding low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma: results of a phase III trial. Swiss Group for Clinical Cancer Research (SAKK).
    Borner MM, Castiglione M, Bacchi M, Weber W, Herrmann R, Fey MF, Pagani O, Leyvraz S, Morant R, Pestalozzi B, Hanselmann S, Goldhirsch A.
    Ann Oncol; 1998 May 10; 9(5):535-41. PubMed ID: 9653495
    [Abstract] [Full Text] [Related]

  • 17. Phase II clinical trial of 5-fluorouracil, trimetrexate, and leucovorin (NFL) in patients with advanced pancreatic cancer.
    Garcia AA, Leichman L, Baranda J, Pandit L, Lenz HJ, Leichman CG.
    Int J Gastrointest Cancer; 2003 May 10; 34(2-3):79-86. PubMed ID: 15361639
    [Abstract] [Full Text] [Related]

  • 18. A phase II trial of weekly high dose continuous infusion 5-fluorouracil plus oral leucovorin in patients with advanced colorectal cancer. The Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD).
    Aranda E, Cervantes A, Dorta J, Blanco E, Fernández-Martos C, Cruz-Hernandez JJ, Carrato A, Gonzalez-Mancha R, García-Conde J, Díaz-Rubio E.
    Cancer; 1995 Aug 15; 76(4):559-63. PubMed ID: 8625147
    [Abstract] [Full Text] [Related]

  • 19. Phase I clinical and pharmacologic trial of trimetrexate in combination with 5-fluorouracil.
    Hudes GR, LaCreta F, DeLap RJ, Grillo-Lopez AJ, Catalano R, Comis RL.
    Cancer Chemother Pharmacol; 1989 Aug 15; 24(2):117-22. PubMed ID: 2525077
    [Abstract] [Full Text] [Related]

  • 20. Biochemical modulation of 5-fluorouracil by leucovorin with or without interferon-alpha-2c in patients with advanced colorectal cancer: final results of a randomised phase III study.
    Hausmaninger H, Moser R, Samonigg H, Mlineritsch B, Schmidt H, Pecherstorfer M, Fridrik M, Kopf C, Nitsche D, Kaider A, Ludwig H.
    Eur J Cancer; 1999 Mar 15; 35(3):380-5. PubMed ID: 10448286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.